BiotechTube

rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX)

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ebola Virus Disease

Conditions

Ebola Virus Disease

Trial Timeline

Apr 9, 2021 → Aug 9, 2022

NCT ID
NCT05130398

About rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX)

rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX) is a phase 1/2 stage product being developed by Merck for Ebola Virus Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05130398. Target conditions include Ebola Virus Disease.

What happened to similar drugs?

2 of 4 similar drugs in Ebola Virus Disease were approved

Approved (2) Terminated (1) Active (1)
✅rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)MerckApproved
🔄V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
✅BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GPMerckApproved
❌Ad26.ZEBOV + MVA-BN-FiloBavarian NordicPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05130398Phase 1/2Completed

Competing Products

20 competing products in Ebola Virus Disease

See all competitors
ProductCompanyStageHype Score
Ad26.ZEBOV vaccineJohnson & JohnsonPhase 2
35
V920 VaccineMerckPhase 1
29
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)MerckPhase 2
39
rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)MerckApproved
50
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus VaccineMerckPhase 2
35
V920MerckPhase 1
29
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
40
BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GPMerckApproved
50
V920MerckPhase 1
29
GS-5734Gilead SciencesPhase 2
35
REGN3470-3471-3479Regeneron PharmaceuticalsPre-clinical
30
Ervebo + InmazebRegeneron PharmaceuticalsPhase 2
42
AVI-7537United TherapeuticsPhase 1
18
Placebo + AVI-6002United TherapeuticsPhase 1
26
Ad26.ZEBOV + MVA-BN-FiloBavarian NordicPhase 3
29
CMX001Jazz PharmaceuticalsPhase 2
24
BrincidofovirJazz PharmaceuticalsPhase 2
24
cAd3-Marburg + cAd3-EBO-SICON plc.Phase 1
26
Base Dose EBOV GP Vaccine + 2x Base Dose EBOV GP Vaccine + 4x Base Dose EBOV GP Vaccine + 8x Base Dose EBOV GP Vaccine + Placebo + Matrix-M AdjuvantNovavaxPhase 1
23
TKM-100802 for Injection + PlaceboArbutus BiopharmaPhase 1
15